Q4 2024 Vivos Therapeutics Inc Earnings Call Transcript
Key Points
- Vivos Therapeutics Inc (VVOS) increased product revenue by 26% in 2024 while reducing operating expenses by 21%, leading to a 35% reduction in operating loss.
- The company successfully launched its expansion into the Middle East, gaining regulatory approvals in several key markets, with demand exceeding forecasts.
- Vivos Therapeutics Inc (VVOS) raised approximately $17.9 million through equity transactions, including a significant $7.5 million investment from New Seneca Partners.
- The new marketing and distribution strategy focuses on profit-sharing alliances and acquisitions of sleep testing clinics, potentially increasing revenue and profit per case.
- The company reported a 70% conversion rate of OSA patients into Vivos treatment options, with a realized top-line revenue of over $4,500 per case and contribution margins of up to 50%.
- Despite revenue growth, Vivos Therapeutics Inc (VVOS) is still using cash to fund operations and will require additional financing in the near term.
- The decrease in VIP enrollments led to a $400,000 reduction in service revenue, reflecting a shift in the company's marketing and sales strategy.
- The company faces challenges in scaling its new business model, including the need to train and integrate dentists into the new system.
- Vivos Therapeutics Inc (VVOS) recorded a net cash used in operations of $12.7 million in 2024, an increase from $11.9 million in the previous year.
- The company is still in the early stages of its strategic pivot, with revenue from new alliances like Rebis expected to show significant impact only in 2025.
Good day, everyone, and welcome to the Vivos Therapeutics Full Year 2024 Earnings Conference Call. (Operator Instructions) This conference call is being recorded, and a replay of today's call will be available on the Investor Relations section of Vivos' website and will remain posted there for the next 30 days. I will now hand the call over to Brad Ammon, Vivos' Chief Financial Officer, for introductions and the reading of the safe harbor statement. Please go ahead, Brad.
Thank you, Jenny. Hello, everyone, and welcome to our 2024 earnings conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.vivos.com. With us on today's call are myself and Kirk Huntsman, Vivos' Chairman and Chief Executive Officer. Today, we will review positive highlights and financial results for the full year 2024 as well as key recent developments in our marketing and distribution strategy pivot.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
